Stanley Laman Group, Ltd. Neurocrine Biosciences Inc Transaction History
Stanley Laman Group, Ltd.
- $648 Million
- Q3 2024
A detailed history of Stanley Laman Group, Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Stanley Laman Group, Ltd. holds 37,531 shares of NBIX stock, worth $4.72 Million. This represents 0.67% of its overall portfolio holdings.
Number of Shares
37,531
Previous 27,443
36.76%
Holding current value
$4.72 Million
Previous $3.78 Million
14.35%
% of portfolio
0.67%
Previous 0.59%
Shares
7 transactions
Others Institutions Holding NBIX
# of Institutions
625Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.78 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.26 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$647 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$323 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$234 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...